NCT05580510: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- State
- State not given
- Phase
- Phase 2 and Phase 3
- People
- 160 planned
- Started
- 6 Feb 2023
- Primary completion
- 28 Jul 2023
- Arms
- Conventional treatment plus Empagliflozin and Sacubitril/valsartan, Conventional treatment plus Empagliflozin
- Results
- None posted
- Papers
- doi:10.1002/ejhf.1342, doi:10.1056/nejmoa2022190, doi:10.1093/eurheartj/ehaa1012, doi:10.1161/circulationaha.120.052186, doi:10.1161/circulationaha.121.053659
- 14 Oct 2022: Trial registered